Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 44 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

6 trials in Phase 3/4

Results Transparency

8%

1 of 12 completed trials have results

Key Signals

12 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
11(36.7%)
N/A
8(26.7%)
Phase 4
3(10.0%)
Phase 3
3(10.0%)
Early Phase 1
3(10.0%)
Phase 1
2(6.7%)
30Total
Phase 2(11)
N/A(8)
Phase 4(3)
Phase 3(3)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT06836869Not ApplicableRecruiting

Modified Tumor-free Techniques Operation to Cervical Cancer

Role: collaborator

NCT03657732Recruiting

The Chinese Familial Alzheimer's Network

Role: collaborator

NCT03653156Recruiting

China Cognition and Aging Study

Role: collaborator

NCT07459296Phase 3Recruiting

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Role: collaborator

NCT07303283Phase 2Not Yet Recruiting

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Role: collaborator

NCT05340270Phase 2Active Not Recruiting

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT07263607Phase 2Not Yet Recruiting

A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis

Role: collaborator

NCT03649503Recruiting

The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

Role: collaborator

NCT07154680Completed

Ophthalmic Diseases and AI: an RCT Study

Role: collaborator

NCT07003191Active Not Recruiting

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Role: collaborator

NCT06992128Phase 2Recruiting

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Role: collaborator

NCT05894148Phase 1Completed

Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults

Role: collaborator

NCT05547750Not ApplicableCompleted

Effect of Vitamin K2 in the Treatment of Nocturnal Leg Cramps in Older Population

Role: collaborator

NCT06742450Not ApplicableRecruiting

Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease

Role: collaborator

NCT06095206Phase 1Completed

The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site

Role: collaborator

NCT06457269Not ApplicableCompleted

Evaluating the Potential of Large Language Models for Respiratory Disease Consultations

Role: collaborator

NCT06627985Not Yet Recruiting

Multi-Disciplinary Treatment on the Anthropomorphism of Large Language Models

Role: collaborator

NCT06562738Phase 4Recruiting

Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

Role: collaborator

NCT06086457Phase 3Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Role: collaborator

NCT06251388Phase 2Recruiting

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer

Role: collaborator